Sleeping sickness and the brain

Cellular and Molecular Life Sciences

Volumn 59, Issue 5, 2002, Pages 845-858

  Enanga, B ^a   Burchmore, R J S ^a   Stewart, M L ^a   Barrett, M P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Blood brain barrier; Central nervous system; Chemotherapy; Sleeping sickness; Trypanosome

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; ANTITRYPANOSOMAL AGENT; DB 289; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CIRCADIAN RHYTHM; CIRCULATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG PENETRATION; HOST; HUMAN; LUMBAR PUNCTURE; MICROSCOPY; NEPHROTOXICITY; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; REVIEW; SKIN DISEASE; TRYPANOSOMA;

ANIMALS; ANTIGENS, PROTOZOAN; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM PROTOZOAL INFECTIONS; CEREBROSPINAL FLUID; CYTOKINES; HUMANS; NITRIC OXIDE; PROSTAGLANDINS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

TRYPANOSOMA;

EID: 0036280334     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-002-8472-0     Document Type: Review

References (136)

1. Traitement de la trypanosomose humaine Africaine en milieu hospitalier
2. Symptomatologie generale de la THA au moment du depistage
3. Circadian disorders in sleeping sickness
4. Sleep-wake cycle in human African trypanosomiasis
5. Nervous system dysfunctions in African trypanosomiasis
6. Human African trypanosomiasis
7. Blood-brain barrier and infections
8. Cellular immune reactivity within the CNS
9. Leukocyte adhesion to endothelium in inflammation
10. Adhesion molecules on murine brain microvascular endothelial cells: Expression of ICAM-1 and LGP 55
11. The influence of cytokines on the integrity of the blood-brain barrier in vitro
12. Prostaglandins, prostacyclin and thromboxane A2
13. Induction of nitric oxide synthetase in rat C6 glioma cells
14. Entry of pathogens into the central nervous system
15. Human African trypanosomiasis
16. Spread of Trypanosoma brucei to the nervous system: Early attack on the circumventricular organs and sensory ganglia
17. Choroid plexus: Target for systemic disease and pathway to the brain
18. Trypanosoma brucei and the nervous system
19. Trypanosoma brucei brucei: A long-term model of human African trypanosomiasis in mice, meningo-encephalitis, astrocytosis, and neurological disorders
20. Molecular and cellular mechanisms for microbial entry into the CNS
21. Trypanosoma brucei brucei crosses the blood-brain barrier while tight junction proteins are preserved in a chronic disease model
22. Cryptic stage of sleeping-sickness trypanosome developing in choroid plexus epithelial cells
23. Infection of organotypic slice cultures from rat central nervous tissue with Trypanosoma brucei brucei
24. Survival of Trypanosoma brucei brucei in cerebrospinal fluid
25. Arsenical-resistant trypanosomes lack an unusual adenosine transporter
26. Developmental cycles and biology of pathogenic trypanosomes
27. African trypanosomiasis
28. Multiple mechanisms of immune evasion by African trypanosomes
29. Immunology and immunopathology of African trypanosomiasis
30. Trypanosoma brucei gambiense: Cerebral immunopathology in mice
31. African trypanosomiasis and drug-induced encephalopathy: Risk factors and pathogenesis
32. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia
33. Treatment of human African trypanosomiasis
34. Human African trypanosomiasis: Presence of antibodies to galactocerebrosides
35. Central nervous system involvement in African trypanosomiasis: Presence of anti-galactocerebroside antibodies in patients' cerebrospinal fluid
36. Detection and characterization of antibodies directed against neurofilament proteins during human African trypanosomaisis
37. Circulating antibodies directed against tryptophan-like epitopes in sera of patients with human African trypanosomiasis
38. Immune complexes in serum and cerebrospinal fluid in African trypanosomiasis: Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis
39. Expression and localization of serum resistance associated protein in Trypanosoma brucei rhodesiense
40. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense
41. Bidirectionnal activating signals between Trypanosoma brucei and CD8+ T-cells: A trypanosome-released factor triggers interferon-gamma production that stimulates parasite growth
42. Typanosomiasis and the nervous system: Pathology and immunology
43. Disruption in the secretion of cortisol, prolactin, and some cytokines in human African trypanosomiasis
44. Increased levels of antibodies to IFN-gamma in human and experimental trypanosomiasis
45. Bi-directional signals between Trypanosoma brucei brucei and dorsal root ganglion neurons
46. T lymphocyte-triggering factor of African trypanosomes is associated with the flagellar fraction of the cytoskeleton and represents a new family of proteins that are present in several divergent eukaryotes
47. Human macrophage tumor necrosis factor (TNF-α) production induced by Trypanosoma brucei gambiense and the role of TNF-α in parasite control
48. Correlation of high serum levels of tumor necrosis factor alpha with disease severity in human African trypanosomiasis
49. Resistance to African trypanosomes is interferon-γ dependent
50. Control of parasitemia and survival during Trypanosoma brucei brucei infection is related to strain dependent ability to produce interleukin-4
51. Alternative versus classical macrophage activation during experimental African trypanosomiasis
52. Relative contribution of interferon-γ and interleukin-10 to resistance to murine African trypanosomiasis
53. The blood-brain barrier in neuroinflammatory diseases
54. Nitric oxide mediated cytostatic activity on Trypanosoma brucei gambiense and Trypanosoma brucei brucei
55. Nitric oxide mediates suppression of T-cell response in murine Trypanosoma brucei infection
56. Nitricoxide-induced inhibition of glyceraldehyde-3-phosphate dehydrogenase may mediate reduced endothelial cell monolayer integrity in an in vitro model blood-brain barrier
57. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide
58. Peroxynitrite oxidation of sulfhydryls: The cytotoxic potential of superoxide and nitric oxide
59. Nitric oxide redox species exert differential permeability effects on the blood-brain barrier
60. Toxic effect of sulphite in combination with peroxynitrite on neuronal cells
61. Inducible nitric oxide synthase and nitrotyrosine in the central nervous system of mice chronically infected with Trypanosoma brucei brucei
62. S100 beta induces neuronal cell death through nitric oxide release from astrocytes
63. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis
64. The somnogenic T-lymphocyte suppressor prostaglandin D2 is selectively elevated in cerebrospinal fluid of advanced sleeping sickness patients
65. Prostaglandin D2 and sleep
66. Molecular mechanisms of sleep-wake regulation: Roles of prostaglandins D2 and E2
67. Sleeping sickness: A disease of clock with nitric oxide involvement
68. Reversal of the sleep/wake cycle disorder of sleeping sickness after trypanocide treatment
69. Blood-brain barrier damage in experimental African trypanosomiasis
70. Cytokine network regulating terminal maturation of human bone marrow B cells capable of spontaneous and high rate Ig secretion in vitro
71. Effect of lipopolysaccharide on the permeability and reactivity of the cerebral microcirculation: Role of inducible nitric oxide synthase
72. Human African trypanosomiasis (Trypanosoma brucei gambiense): A study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy
73. Human African trypanosomiasis: Use of double centrifugation of cerebrospinal fluid to detect trypanosomes
74. A cardagglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. b. gambiense trypanosomiasis
75. Use of polymerase chain reaction in human African trypanosomiasis stage determination and follow-up
76. Detection of trypanosomes in suspected sleeping sickness patients in Uganda using the polymerase chain reaction
77. Single centrifugation of cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of trypanosomes
78. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: A randomised trial
79. Current situation of African trypanosomiasis
80. Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis
81. Clinical and pathological aspects of human African trypanosomiasis (Trypanosoma brucei gambiense) with particular reference to reactive arsenical encephalopathy
82. The treatment of human African trypanosomiasis
83. Pharmacokinetic properties of the trypanocidal drug melarsoprol
84. Pharmacokinetics of melarsoprol in uninfected vervet monkeys
85. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized
86. Investigations of the metabolites of the trypanocidal drug melarsoprol
87. MelB in the treatment of human trypanosomiasis
88. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment
89. The phenomenon of treatment failures in human African trypanosomiasis
90. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda
91. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda
92. Polyamine metabolism: A potential therapeutic target in trypanosomes
93. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine
94. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness
95. Short-course eflornithine in Gambian trypanosomiasis: A multicentre randomized controlled trial
96. Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair
97. Pentamidine, a review
98. Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Cote d'Ivoire
99. The efficacy of pentamidine in the treatment of early - Late stage Trypanosoma brucei gambiense trypanosomiasis
100. Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness
101. African trypanosomiasis research: 100 Years of progress, but questions and problems still remain
102. A chlorodiazirine analog of pentamidine with anti-trypanosomal activity
103. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: An open trial in central Zaire
104. New therapeutic regimen for sleeping sickness: Description, results and lessons from the clinical trial established in Bwamanda (Equateur RDC)
105. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice
106. Experimental models for new chemotherapeutic approches to human African trypanosomiasis
107. Uptake of the nitroimidazole drug megazol by African trypanosomes
108. A nucleoside transporter from Trypanosoma brucei involved in drug resistance
109. Megazol combined with suramin: A chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice
110. Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals
111. Pharmacokinetics, metabolism and excretion of megazol in a Trypanosoma brucei gambiense primate model of human African trypanosomiasis: Preliminary study
112. Simple high-performance liquid chromatographic method to analyse megazol in human and rat plasma
113. Co-operative binding sites for transported substrates in the multiple drug resistance transporter Mdr1
114. CL 64,855, a potent anti-Trypanosoma cruzi drug, is also mutagenic in Salmonella microsome assay
115. Purification and characterisation of wild-type and mutant 'classical' nitroreductases of Salmonella typhimurium: L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium
116. 2-Amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole, a new antimicrobial agent. VI. Antibacterial efficacy in mice and in vitro
117. 2-Amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole, a new antimicrobial agent. IX. Action against hemoflagellate infections in laboratory animals
118. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems
119. Breaching the blood-brain barrier
120. The blood-brain barrier efflux transporters as a detoxifying system for the brain
121. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
122. P-Glycoprotein limits oral availability, brain and fetal penetration of Saquinar even with high doses of Ritonavir
123. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery
124. Drug delivery via the blood-brain barrier
125. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice
126. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat
127. Decerased expression and activity of P-glycoprotein in rat liver during acute inflammation
128. Chemotherapy of CNS-trypanosomiasis: Combination chemotherapy with 5-nitroimidazole (MK 436), an arsenical (Cymelarsan) and suramin
129. New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin
130. ATP-dependent astrocyte-endothelial calcium signaling following mechanical damage to a single astrocyte in astrocyte-endothelia co-cultures
131. The development of the bradykinin agonist Labradimil as a means to increase the permeability of the blood-brain barrier
132. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes
133. High-throughput prediction of blood-brain partitioning: A thermodynamic approach